Histogenics (NASDAQ:HSGX) is scheduled to release its earnings data before the market opens on Thursday, November 8th. Analysts expect Histogenics to post earnings of ($0.18) per share for the quarter.
Histogenics (NASDAQ:HSGX) last issued its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.10. On average, analysts expect Histogenics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of HSGX stock opened at $0.68 on Thursday. Histogenics has a 1-year low of $0.50 and a 1-year high of $3.35. The firm has a market cap of $22.92 million, a PE ratio of -0.70 and a beta of 1.79.
HSGX has been the topic of a number of research analyst reports. Needham & Company LLC lifted their price target on Histogenics to $5.00 and gave the company a “buy” rating in a report on Thursday, September 6th. Zacks Investment Research downgraded Histogenics from a “hold” rating to a “sell” rating in a report on Thursday, October 11th. HC Wainwright reiterated a “buy” rating and set a $2.00 price target on shares of Histogenics in a report on Wednesday, September 5th. BTIG Research downgraded Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 price target on the stock. in a report on Wednesday, September 5th. Finally, Brookline Cap M reiterated a “buy” rating on shares of Histogenics in a report on Wednesday, August 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $3.45.
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
See Also: Trading Strategy Examples and Plans
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.